Companies › Neurimmune
1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALXN2220 anti-transthyretin (TTR) monoclonal antibody | TTR | Phase 2 | Amyloid Transthyretin Cardiomyopathy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07213583 | ALXN2220 | Phase 2 | Amyloid Transthyretin Cardiomyopathy | Cardiovascular | Oct 2026 |
Alnylam Pharmaceuticals AstraZeneca Novo Nordisk Intellia Therapeutics Eidos Therapeutics, a BridgeBio company Ionis Pharmaceuticals Qilu Pharmaceutical
Eidos Therapeutics, a BridgeBio company Tectonic Operating Company CuraSen Therapeutics Seismic Pharmaceuticals Operations Foresee Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.